Lifera

Lifera is a biopharmaceutical company wholly owned by the Public Investment Fund (PIF) with a mission to enable two national priority objectives, which are improving Saudi Arabia’s biopharma resilience, and enabling the achievement of the National Biotech Strategy. To achieve this mission, Lifera aims to become a leading biopharma Contract Development and Manufacturing Organization (CDMO) with a focus on advanced therapeutics and critical medicines. Lifera’s strategy is to be a service provider to biopharma and biotech companies globally by developing and acquiring state-of-the-art cGMP biomanufacturing capacity, establishing high throughput multi-omics capacity to support clinical, population health and R&D customers, securing high-value commercial partnerships and technology transfer, and developing a high caliber biopharma workforce. Lifera serves customers for both KSA and global markets through contract manufacturing of biologics including insulin, vaccines, monoclonal antibodies, gene therapies, and other advanced medicinal products, as well as through genetic testing services with a global presence and depth in rare disease with plans to expand into other therapeutic areas.

riyadh pharma

Riyadh Pharma was established in the year 1994, in the industrial area about 30 Km from the city of Riyadh. The total building area is about 22000 m² occupying a land area of 15000 m². The manufacturing facilities are capable of producing over 100 generic and licensed products to the highest global standards required by the licensors for local and international markets. Efficiency and specialized knowledge of manufacturing and sales will ensure the profitable nature of our clients business. Riyadh Pharma's operation is secured by an experienced financial organization, which ensured that the company was provided with premium quality, state-of-the-art equipment and facilities coupled with highly experienced and qualified personnel. The plant installed by the Medical & Cosmetic Products Co. Ltd (Riyadh Pharma) was licensed by the Ministry of Industry in 1994.

Sudair Pharmaceutical Company

Sudair pharma is a Saudi-Based company, established in 2014 for purpose of building an advanced pharmaceutical manufacturing complex to combat chronic & life threatening diseases sudair pharma vision is fulfilling the unmet needs in pharmaceutical sector in the Saudi Arabia and MENA region. and also our mission to establishing and localizing Advanced Pharmaceutical-Biologics Industrial Group (APBIG) to improve healthcare provision and the reach to latest pharmaceuticals in Saudi Arabia and MENA region through building a local specialized professional team, international partnership and affiliations. SPC owns the land in Sudair Industrial City (100 km North of Riyadh City) encompassing more than 77,000 square meter. At this manufacturing site, the land will be equitably distributed to major pharmaceutical industry groups as joint ventures to construct manufacturing facilities. sudair pharma project is divided into several stages, first stage which is the establishment of oncology medicine plant.

saja pharmaceuticals

SAJA is a joint venture between the premier Saudi healthcare company Tamer Industries and two of the leading Japanese pharmaceutical companies which are Daiichi Sankyo Company Ltd and Astellas Pharma Inc.

Jamjoom Pharma

Jamjoom Pharma has in a very short span of time emerged, as one of the leading pharmaceutical companies in the Afrasia region. The geographical focus of the company is on countries in the Middle East, Africa and CIS regions. Strategic focus on selected therapeutic categories has contributed to the rapid growth, market acceptance and overall success of the company. The Manufacturing Facilities and Head Office are located in the port city of Jeddah in Saudi Arabia. Jamjoom Pharma has state-of-the-art manufacturing facilities which encapsulates the latest in manufacturing technology, systems and business practices. The facility has aroused the attention and admiration of the professionals from international pharmaceutical industry. The company continuously keeps abreast of the latest developments in Pharma manufacturing technology and practices, and readily adopts and integrates these into the existing manufacturing systems and practices based on rigorous cost benefit analysis. From the outset, Jamjoom Pharma has laid great emphasis on attracting and retaining key talent from international pharmaceutical companies in manufacturing as well as in other departments.